The Alvin J. Siteman Cancer Center (SCC) at Washington University School of Medicine and Barnes-Jewish Hospital was first designated as a Clinical Cancer Center in 2001, and as a Comprehensive Cancer Center in 2004. The SCC is composed of eight multidisciplinary research programs: Cancer &Developmental Biology, Tumor Immunology, Hematopoietic Development &Malignancy, Cellular Proliferation, Prevention & Control, Translational &Clinical Research, Oncologic Imaging, and the Breast Cancer Research Program. Research efforts in the programs are supported by 13 shared resources, two of which are under development: Embryonic Stem Cell Core;Tissue Procurement Core;Molecular and Genomic Analysis Core; Small Animal Cancer Imaging Core;High Speed Cell Sorter Core;Health Behavior, Communication and Outreach Core;Proteomics Core, Biomedical Informatics Core, Imaging Response Assessment Team, Biostatistics Core, Clinical Trials Core, High Throughput Screening Core (developing), and Dissemination & Implementation Core (developing). Since submission of the first Cancer Center Support Grant application in October 2000, the SCC has made significant progress. Overall cancer-related grant funding has increased nearly 100% to $152.8 million, and NCI funding has more than doubled to $55.2 million, while membership has increased only modestly to 270 research and research associate members. Interdisciplinary coordination and collaboration has been significantly enhanced through the full integration ofthe Genome Center (GC) in the SCO's research programs. Four key themes are used strategically to drive transdisciplinary research across the SCC - Cancer Genomics, Developmental Therapeutics, Novel/Molecular Diagnostics, and Dissemination and Implementation. Key indicators of progress include an increase in intra- and inter-programmatic publications to 31% in 2009;and an increase in the number of integrated, multidisciplinary, programmatic grants from 8 in 2000 to 17 in 2003, to 40 in 2009. This progress is directly attributable to a productive membership that is tightly focused on cancer research, research infrastructure strategically developed to meet the needs ofthe members, and engaged Senior Leaders who are committed to fostering collaborative, translational research.

Public Health Relevance

The goals ofthe Siteman Cancer Center are to foster research productivity, promote interaction and collaboration, and take maximum advantage of institutional strengths and unique scientific opportunities to advance cancer diagnosis, treatment, and prevention for our patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA091842-09S3
Application #
8136809
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
2001-08-02
Project End
2015-06-30
Budget Start
2010-09-22
Budget End
2011-06-30
Support Year
9
Fiscal Year
2010
Total Cost
$49,953
Indirect Cost
Name
Washington University
Department
Surgery
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Mostafa, Heba H; Thompson, Thornton W; Konen, Adam J et al. (2018) Herpes Simplex Virus 1 Mutant with Point Mutations in UL39 Is Impaired for Acute Viral Replication in Mice, Establishment of Latency, and Explant-Induced Reactivation. J Virol 92:
Choi, Jaebok; Cooper, Matthew L; Staser, Karl et al. (2018) Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32:2483-2494
Bartlett, Nancy L; Costello, Brian A; LaPlant, Betsy R et al. (2018) Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood 131:182-190
Kalas, Vasilios; Hibbing, Michael E; Maddirala, Amarendar Reddy et al. (2018) Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection. Proc Natl Acad Sci U S A 115:E2819-E2828
Yokoyama, Christine C; Baldridge, Megan T; Leung, Daisy W et al. (2018) LysMD3 is a type II membrane protein without an in vivo role in the response to a range of pathogens. J Biol Chem 293:6022-6038
Miller, Jessica; Wang, Steven T; Orukari, Inema et al. (2018) Perfusion-based fluorescence imaging method delineates diverse organs and identifies multifocal tumors using generic near-infrared molecular probes. J Biophotonics 11:e201700232
Song, Wilbur M; Joshita, Satoru; Zhou, Yingyue et al. (2018) Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med 215:745-760
Gauvain, Karen; Ponisio, Maria Rosana; Barone, Amy et al. (2018) 18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors. Neurooncol Pract 5:28-36
Cruchaga, Carlos; Del-Aguila, Jorge L; Saef, Benjamin et al. (2018) Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement 14:205-214
Willet, Spencer G; Lewis, Mark A; Miao, Zhi-Feng et al. (2018) Regenerative proliferation of differentiated cells by mTORC1-dependent paligenosis. EMBO J 37:

Showing the most recent 10 out of 1244 publications